Hemispherx Biopharma has entered into a clinical trial, sales, marketing, distribution and supply agreement with Scientific Products Pharmaceutical (SCIEN) located in Riyadh, Saudi Arabia. The contract covers Saudi Arabia, United Arab Emirates, Kuwait, Oman, Qatar and Bahrain, expanding Hemispherx’s early access programs (EAP) globally. The agreement also calls for SCIEN to purchase certain quantities of Hemispherx’s clinical grade interferon alfa-n3 for investigative use in individuals...